News & Media
Read the latest news and updates from ELIAS Animal Health
Promising New Data Demonstrates Chemo-Immunotherapy Treatment Approach with ECI® Significantly Improves Outcomes in Dogs with Bone Cancer
LENEXA, Kan. – September 23, 2025 – ELIAS Animal Health, a leader in advancing novel therapies for veterinary cancer care, has published new data from its ASCENT study evaluating a novel chemo-immunotherapy regimen for canine osteosarcoma, an aggressive and often fatal bone cancer in dogs. The analysis was recently presented at the 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities and will be discussed in detail at the upcoming 2025 Veterinary Cancer Society Annual Conference. The ASCENT study investigated a treatment strategy that integrates a single dose of chemotherapy followed by the ELIAS [...]
ELIAS Animal Health to Present New Research at Upcoming Human and Veterinary Oncology Conferences
LENEXA, Kan., September 4, 2025 -- ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising new research on its novel chemo-immunotherapy approach for canine osteosarcoma at two upcoming scientific meetings in September 2025. 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities, being held September 18–21, 2025, in Baltimore, Md. The presentation will highlight the safety and efficacy of integrating traditional cytotoxic chemotherapy with a vaccine-enhanced adoptive cell therapy in canine osteosarcoma, a well-known translational model for pediatric osteosarcoma in humans. 2025 Veterinary Cancer [...]
New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes
LENEXA, Kan., June 19, 2025 – ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical study evaluating ELIAS Cancer Immunotherapy (ECI®), a USDA-approved autologous prescription product, combined with chemotherapy for treatment of osteosarcoma, an aggressive form of bone cancer in dogs. The interim analysis, presented at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, KY, demonstrated that combining the initial cytotoxic effects of chemotherapy with the targeted immune-mediated response stimulated by ECI® has the potential to enhance overall response and survival rates in canine cancer patients. The [...]